News | January 26, 2010

Thoratec Acquires Catheter-Based Heart Pump Technology

January 26, 2010 – Surgical ventricular assist device (VAD) maker Thoratec Corp. acquired a catheter-based pump technology and plans to develop a minimally invasive, axial flow pump that can be delivered percutaneously in the cardiac catheterization lab.

Thoratec is paying a cash purchase price of $8.5 million to Getinge AB for the technology. The company expects to incur incremental development costs of up to $3 million in 2010

Thoratec said it plans to offer a device that can provide fast and minimally invasive acute cardiac support for hemodynamically unstable acute myocardial infarction, high-risk percutaneous coronary intervention and post-cardiotomy patients. The company said the device will provide greater flow rates and a smaller size than existing devices. Thoratec expects to commercialize the device in the next several years.

Known as a PHP (percutaneous heart pump), the device is an axial flow pump, which is inserted through an 11 French introducer sheath that is expandable to 21 French, with an elastomeric, collapsible impeller and cannula that is driven by an external motor via a flexible drive shaft. In a laboratory setting, the device has generated greater than 4.5 liters per minute of flow against normal physiological pressures.

"We already have a very robust product pipeline that includes continued enhancements to our HeartMate II platform, including the recently announced smaller version of the HeartMate II, and our fully magnetically levitated HeartMate III. This transaction provides a unique opportunity to develop a device that complements and expands upon our existing MCS offerings," said Gary F. Burbach, president and chief executive officer of Thoratec.

For more information: www.thoratec.com, www.itcmed.com

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init